Martin Silva 25:03 Hey man, let me let me let me touch on that real quick because that's such an important point you make, is the behavioral aspect
Tirzepatide (brand names Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that produces higher average weight loss, roughly 18 to 25% of body weight in clinical trials
These data were published in Otolaryngology-Head and Neck Surgery
Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter
Compounding advocates say that, although the drugs are not FDA-approved, they are still subject to rigorous quality control, in part due to post-2012 rule changes
Many people experience B12 deficiencies that can lead to fatigue, cognitive issues, and weakened immune function